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Abstract
Background Acute kidney injury (AKI) is the most common
complication of perinatal asphyxia. Recent research indicates
that urine neutrophil gelatinase-associated lipocalin (NGAL)
is an early marker for AKI; yet, there is a paucity of data about
its use in term neonates with perinatal asphyxia.
Methods A prospective cohort study was conducted on 108
term babies in the new-born unit of Pumwani Maternity
Hospital and Kenyatta National Hospital. Urine NGAL and
serum creatinine were measured in 108 term asphyxiated
neonates on days 1 and 3 of life.
Results One-hundred and eight patients were recruited
(male:female 1.4:1). At a cut-off of 250 ng/ml, urine NGAL
had an acceptable discriminative capability of predicting AKI
(area under the curve 0.724). The sensitivity, specificity, pos-
itive and negative predictive value and likelihood ratios were
88, 56, 30, 95 %, 2 and 0.2 respectively. Urine NGAL levels
were significantly higher in patients with AKI compared with
those without AKI. An NGAL level greater than 250 ng/ml on
day 1 was significantly associated with severe hypoxic isch-
aemic encephalopathy (HIE); odds ratio=8.9 (95 % CI 1.78–
37.69) and mortality; odds ratio=8.9 (95 % CI 1.78–37.69).
Conclusion Urine NGAL is a good screening test for the early
diagnosis of AKI. It is also a predictor of mortality and
severity of HIE in asphyxiated neonates.
Keywords Neutrophil gelatinase-associated lipocalin . Acute
kidney injury . Perinatal asphyxia
Introduction
Acute kidney injury (AKI) has emerged as an important health
problem in the neonatal population and the care of a child with
renal disease has evolved dramatically over the last few de-
cades. The most common complication of perinatal asphyxia
is AKI and the current gold standard for the diagnosis of AKI
is based on serum creatinine. With all its shortcomings as a
diagnostic test, serum creatinine continues to be the marker of
choice in the diagnosis of AKI. Creatinine is a late marker of
AKI and therefore the search continues for a new biomarker
that can replace this imperfect gold standard test with the sole
objective of providing an early and accurate diagnosis of AKI
in the new-born and in the population in general.
Most of the prevalence studies that have investigated AKI
in new-borns have been single-centre studies and report its
existence to be between 17.2 and 61 % [1–4].
The lack of a consensus definition and classification criteria
of AKI in neonates is mainly due to the paucity of measurable
variables and biochemical markers [5]. This has led to diffi-
culty in accurately estimating the prevalence of AKI in new-
borns, as different studies have used various definitions and
cut-offs of serum creatinine to define AKI. The majority of the
neonatal studies use a serum creatinine measurement cut-off
of 133 μmol/l.
Serum creatinine is currently the gold standard test for
diagnosing AKI; yet, it possesses significant shortcomings
and is acknowledged to be an inadequatemarker of renal injury.
Furthermore, the problem with using creatinine as a measure of
AKI in neonates is that serum creatinine in the first 24–48 h
reflects maternal creatinine, rendering it an unhelpful test in the
immediate diagnosis of AKI in the post-natal period [6].
Overall, glomerular filtration rate (GFR) in neonates, both
term and preterm, is very low and there is a wide distribution
of normal creatinine values, making it difficult to use to assess
renal function [7].
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Oliguria, a clinical sign of AKI, is not a consistent finding
in neonates with perinatal asphyxia, where over 50 % of cases
of AKI may occur in the absence of oliguria [3, 5].
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-
kDa member of the lipocalin family and its small size makes it
resistant to degradation [8]. NGAL accumulates in the human
kidney cortical tubules, blood and urine at very high levels
post-ischaemic and nephrotoxic injury, and is one of the
earliest proteins induced after kidney injury. Thus, levels of
NGAL significantly rise in the blood and urine soon after AKI
[9, 10].
Lavery et al. were the first to investigate the role of urine
NGAL in premature infants. The sensitivity and specificity of
NGAL in detecting renal impairment by serum creatinine
greater than 1.2 mg/dl (106 μmol/l) were 20 and 88 % respec-
tively [11]. The sensitivity of NGAL in detecting AKI by
oliguria was poor at 31 %, with a specificity of 90 %. This
study concluded that the role of NGAL as an early biomarker
for AKI in preterm neonates warranted further investigation.
A nested case–control study (n=9 AKI, n=24 no AKI) was
performed by Askenazi et al., comparing eight urine AKI
biomarkers in infants with AKI, one of which was NGAL.
AKI was defined as a rise in serum creatinine by 27 μmol/l or
an elevation of 150 μmol/l persisting for 3 days. The study
revealed that for urine NGAL, the area under the curve was
0.68, suggesting the poor discriminative ability of urine
NGAL as a predictor of AKI [12].
In a recent study published in August 2012, Sarafidis et al.
[13] investigated serum and urine AKI biomarkers in 13 as-
phyxiated neonates at term (8 with AKI, 5 without AKI).
Concerning the urine NGAL findings, it was demonstrated that,
compared with controls, significantly higher urine and serum
NGAL levels were noted in the asphyxia AKI group than in the
non-AKI group. Second, urine NGAL had a significant diag-
nostic performance as a predictor of AKI on day 1 of life
(AUC=0.865, sensitivity=100 %, specificity=83.3 %).
This study aimed to investigate the prevalence of AKI
using urine NGAL and to determine the diagnostic utility of
urine NGAL in asphyxiated neonates with AKI compared
with serum creatinine.
Materials and methods
Study design and population
We conducted a hospital-based prospective cohort study at two
new-born units in Pumwani Maternity Hospital and the Ken-
yatta National Hospital, which is representative of the maternal
and new-born population in Nairobi. The study enrolled 108
term neonates and was conducted over a 6-month period.
The sample size used to estimate the prevalence of AKI in
neonates with perinatal asphyxia was calculated using Fisher’s
formula [14], with ±10 % margin of error, assuming a preva-
lence of 61 % [3]. In this study used a confidence interval of
95 % was used to report findings. The reported confidence
interval has a probability of 95 %, including the true popula-
tion prevalence.
The research and ethics board of all the institutions
reviewed and approved the study. Neonates were included in
the study only if informed consent had been given and had
been admitted at term within 24 h of birth with a diagnosis of
perinatal asphyxia. All neonates who were preterm, partici-
pating in another study or transferred to another facility before
day 3 of life, or who had gross congenital malformations, were
excluded from the study.
Neonatal demographic details included gestational age,
weight, gender, Apgar score, time of birth, requirement for
bag mask ventilation, comorbid conditions, use of any neph-
rotoxic medication and hypoxic ischaemic encephalopathy
(HIE) scoring. Perinatal asphyxia was defined as a failure to
initiate sustained breathing at birth plus an Apgar score of less
than 7 at 5 min [15]. The Apgar score is a quantitative score,
usually measured at 1, 5 and 10 min after birth. The infant's
heart rate, respiratory effort, muscle tone, response to stimu-
lation (usually pharyngeal suctioning) and colour are assessed.
For each of these five components, assessors award a maxi-
mum of two points for normal, one point for poor and 0 points
for bad. An Apgar score of less than 7 indicates moderate
neuro-/cardiorespiratory depression, and a score of less than 3
indicates severe depression [16].
Acute kidney injury was defined as serum creatinine
133 μmol/l or a percentage increase in serum creatinine of
≥50 % (1.5-fold from the baseline) [1, 3, 17].
Hypoxic ischaemic encephalopathy in this study was de-
fined as acute neurological injury secondary to perinatal as-
phyxia. Clinically, the assessment was done using the Sarnat
classification [18].
Urine samples for NGAL measurement and blood samples
for creatinine measurement were collected on days 1 and 3 of
life. The urine sample was collected either using a urine bag or
if the patient was already catheterised for any purpose or
required catheterisation, collection was done via a urinary
catheter. For collection via a urine bag the site was cleaned
with normal saline and subsequently a urine bag attached;
once urine was collected into the bag, it was transferred into
a urine container and labelled. The blood sample for serum
creatinine was collected simultaneously with the urine sample.
Samples were immediately stored in an icebox and
transported within 2 h of collection to the Aga Khan Univer-
sity Hospital laboratory for processing.
Serum creatinine assays were carried out immediately
using the creatinine Jaffe gen.2 assay. Urine samples, on the
other hand, were centrifuged at 1,500×g, 4 °C for 15 min to
remove debris and stored in labelled polypropylene tubes at
−70 °C for later measurement. All samples were then tested
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using the ArgutusMedical HumanNGAL ELISA kit (BIO92)
in one batch at the end of data collection.
Before performing the assay, samples were thawed and
brought to room temperature (18–25 °C) and mixed gently.
All samples were prepared before starting the assay. NGAL
analysis by ELISA was performed using the commercially
available assay, which was run according to the manufac-
turer’s protocol. All measurements were run in duplicate to
ensure accuracy.
The NGAL concentration was measured at 450 nm wave-
length. The mean absorbance for each set of duplicate stan-
dards, controls and samples was then calculated. If the indi-
vidual absorbance differed by more than 15 % from the
corresponding mean value, the result was considered suspect
and was retested again. A standard curve was created using
Sigma Plot 10.0, which generated a good curve fit. The mean
absorbance for each standard concentration was plotted on the
vertical (Y) axis versus the corresponding concentration on
the horizontal (X) axis (logarithmic scale).
According to the manufacturer’s protocol, recovery of
NGAL in undiluted samples is not 100 %, hence samples
were diluted by a factor of 20 for NGAL to be measured
accurately. The concentrations read from the standard curve
were then multiplied by the dilution factor to attain the final
concentration of urine NGAL.
Statistical analysis
The use of descriptive statistics has been applied to decipher
the characteristics of the collected data. Categorical
data/variables were summarised using proportions, while con-
tinuous data/variables were summarised using means or me-
dians along with their standard deviations and mean interquar-
tile ranges respectively
Cut-off for urine NGAL
According to the manufacturer, Argutus Medical Company,
the ELISA BIO92 NGAL Kit is a research-based assay;
hence, recommended cut-off values were not provided for a
positive test. Furthermore, a standard cut-off for NGAL con-
centration in the detection of AKI has not yet been reported,
with all existing studies proposing their own cut-offs. There-
fore, this study also determined its own cut-off point using
applied statistical methods.
In current practice for the determination of AKI, the gold
standard test is the use of serum creatinine. Therefore, a
logistic regression model was developed to predict the asso-
ciation between the gold standard and the diagnostic test. The
sensitivity and specificity of the association was generated and
plotted on a graph, and the point of intersection that gave the
best sensitivity and specificity was used as the cut-off point.
The diagnostic accuracy of urine NGAL was then tested by
generating a conventional ROC curve.
To determine the sensitivity and specificity of urine NGAL
in identifying AKI, a 2×2 contingency table was created. The
positive and negative likelihood ratio and positive and nega-
tive predictive values were also analysed.
As urine NGAL on day 1 and serum creatinine of day 3
were non-normally distributed, comparison between the
groups was carried out using the non-parametric Kruskal–
Wallis test. In addition, non-normally distributed data were
expressed using the median. The odds ratio was measured as a
test of association.
Results
One-hundred and eight patients were recruited, of whom 16
died before day 3 of life. Inspection of the collected data
showed that 58.3 % of the neonates were male and 41.7 %
female (male:female ratio 1.4:1). The median (IQR) gestation-
al age was 38 weeks (38, 40) and the mean (±SD) birth weight
was 3,035 g (±399.2). Of the 108 patients, 75 and 24.1 % had
moderate and severe asphyxia respectively. HIE scoring was
coded into severe and non-severe, the distribution of which
was 83.3 and 16.7 % respectively.
Comorbid conditions included neonatal sepsis, respiratory
distress and convulsion, proportions of which are shown in
Table 1.
Table 1 Description of study population (n=108)
Variable Frequency
Sex, %
Male 58.3
Female 41.7
Gestational age, weeks,
median (IQR)
38 (38, 40)
Birth weight, g, mean (±SD) 3035 (399.2)
APGAR score, %
Moderate 75
Severe 24.1
Median APGAR (± SD) 4 (1.4)
HIE, %
Non-severe 83.3
Severe 16.7
Comorbid condition, %
Respiratory distress 1.9
Convulsion 27.8
Suspected sepsis 44.4
More than 1 17.6
None 8.3
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Determination of diagnostic utility of NGAL on day 1
A logistic regressionmodel was used to predict the association
between urine NGAL on day 1 (explanatory/independent
variable) and creatinine ≥133 μmol/l (definition of AKI) on
day 3 of life. A cut-off value was chosen based on previous
studies. A cut-off was preferred rather than analysing it as a
linear regression because the cut-off is more likely to be of
clinical utility. Sensitivity and specificity were calculated and
plotted against each other to determine the point of intersec-
tion that would be the appropriate cut-off value (Fig. 1).
Figure 1 shows the sensitivity and specificity of urine
NGAL for predicting a creatinine of 133 μmol/l. The point
of intersection of sensitivity and specificity was at NGAL
concentration 250 ng/ml, which was chosen as a cut-off.
An area under the ROC curve, shown in Fig. 2, was then
generated to provide a measure of the discriminative capabil-
ity of the logistic model. The area under the curve was found
to be 0.724, which showed that the chosen NGAL cut-off had
an acceptable discrimination.
Prevalence of AKI using urine NGAL ≥250 ng/ml
The cut-off for urine NGAL was determined at 250 ng/ml.
Consequently, the prevalence of AKI using urine NGAL was
found to be 56 % (60 out of 108; 95 % CI 46.6–65.1 %). Of
the 56 % of the patients with AKI, 67 % (40 out of 60) were
male and 33.3% (20 out of 60) were female. In contrast, in the
non-AKI group 47 % were male and 53 % were female. A 2×
2 contingency table was then created to determine the sensi-
tivity, specificity, positive and negative predictive value, the
likelihood ratio and the odds ratio for urine NGAL against the
gold standard. This is given in Table 2.
Table 3 shows the diagnostic utility of urineNGAL as derived
from Table 2. The calculated sensitivity and specificity are 88
and 56 % respectively. A positive likelihood ratio of 2 suggests
that if NGAL is ≥250 ng/ml, the likelihood of having AKI is
higher, whilst the negative likelihood ratio of 0.2 suggests that if
NGAL is <250 ng/ml the patient is highly unlikely to have AKI.
Comparison of survivors and non-survivors
The 16 patients who died had a significantly higher median for
urine NGAL (day 1) 399 ng/ml (IQR 296–448) compared
with those who survived: Kruskal–Wallis, Chi-squared =12.7,
p<0.004.When comparing this with serum creatinine (day 3),
patients who died also had a significantly higher median
serum creatinine of 147.5 μmol/l (IQR 134.5–211.5) com-
pared with those who were alive: Kruskal–Wallis, Chi-
squared=7.185, p<0.0073.
Comparison of severe HIE and non-severe HIE
Patients with severe HIE also had a significantly higher me-
dian NGAL (day 1), 391.9 ng/ml (IQR 296–445) compared
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Fig. 1 Graph of sensitivity vs specificity of urine neutrophil gelatinase-
associated lipocalin (NGAL)
Fig. 2 Receiver operating characteristic (ROC) curve for urine
neutrophil gelatinase-associated lipocalin (NGAL) on day 1
Table 2 2×2 Contingency table for urine NGAL vs the gold standard
Gold standard (serum
creatinine 133 μmol/l), day 3
No AKI AKI Total
Urine NGAL (≥250 ng/ml =
AKI; day 1)
No-AKI 42 2 44
AKI 33 15 48
Total 75 17 92
NGAL neutrophil gelatinase-associated lipocalin, AKI acute kidney injury
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with those with non-severe HIE: Kruskal–Wallis, Chi-squared
=14.5, p<0.0007. However, median serum creatinine for
patients with severe HIE, 115.5 μmol/l (IQR 85–147.5) was
not significantly different from those without severe HIE:
Kruskal–Wallis, Chi-squared =2.7, p<0.255.
Tests of association
An NGAL level greater than 250 ng/ml on day 1 was signif-
icantly associated with severe HIE; odds ratio=8.9 (95 % CI
1.78–37.69). Similarly, a urine NGAL level greater than
250 ng/ml on day 1 was significantly associated with mortal-
ity: odds ratio=8.9 (95 % CI 1.78–37.69). In comparison with
urine NGAL, it was observed that creatinine levels on day 3
greater or equal to 133 μmol/l were not significantly associ-
ated with severity of HIE, maternal and neonatal comorbid
conditions except for outcome p<0.03. On the contrary, urine
NGAL levels greater than 250 ng/ml on day 1 were not
significantly associated with any neonatal or maternal comor-
bid condition (p<0.961 and 0.32 respectively).
Comparison of urine NGAL between days 1 and 3
On day 1 of life, significantly higher urine NGAL levels were
noted in patients with AKI compared with those without AKI.
The levels of NGAL on day 3 remained persistently higher.
The box plots in Fig. 3 summarise this. The first box plot
shows levels on day 1 of patients with and without AKI. The
second box plot shows the same information for day 3.
Discussion
This study investigated the prevalence of AKI in term neo-
nates with perinatal asphyxia. Using urine NGAL, AKI was
present in 60 of the 108 (56 %) infants with asphyxia.
The existing studies report an AKI prevalence of 17.2–
61 % using serum creatinine in term neonates with perinatal
asphyxia. However, because no universal criteria or classifi-
cation exists to define AKI in the new-born, it is difficult to
compare the prevalence between different regions and also
amongst different studies. All studies have used various cut-
off levels of serum creatinine ranging from 90 to 133μmol/l to
define AKI.
For instance, this study used a diagnostic cut-off for serum
creatinine of 133 μmol/l at day 3. Using this cut-off, only
19.5 % of the patients had elevated creatinine >133 μmol/l.
However, if the cut-off was reduced to 90 μmol/l, as used in
another local African study, the prevalence would increase to
57.6 %. Therefore, in a particular study the prevalence of AKI
can be increased by lowering the creatinine cut-off for the
diagnosis of AKI. This makes it difficult to appreciate and
compare the true disease burden between regions owing to the
lack of a universal definition of AKI in new-borns. In our
study we therefore opted to measure the prevalence of AKI
using urine NGAL on day 1.
Eighty-eight per cent of patients with severe HIE devel-
oped AKI using urine NGAL as the biomarker. On the con-
trary, in non-severe HIE, AKI was present in only 16.6 % of
patients. Similar findings of a higher occurrence (61 %) of
AKI amongst severely asphyxiated neonates were reported in
a study carried out in the USA [3].
The results from this study show that the overall prevalence
of AKI is higher in boys than girls, with a ratio of 2.3:1
respectively. These findings are analogous to what has been
Table 3 Results of the diagnostic tests on urine neutrophil gelatinase-
associated lipocalin (NGAL)
Test Result 95 % confidence interval
Sensitivity (%) 88 63.5–98.2
Specificity (%) 56 44.1–67.5
Positive predictive value (%) 31 18.7–46.3
Negative predictive value (%) 95 84.5–99.3
Positive likelihood ratio 2.0 1.4–2.7
Negative likelihood ratio 0.2 0.06–0.8
Fig. 3 Box plots of neutrophil
gelatinase-associated lipocalin
(NGAL) levels on days 1 and 3.
AKI acute kidney injury
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reported in other studies for gender distribution of AKI in the
new-born. Nigerian and Iranian studies [19, 20] indicated a
male-to-female ratio of 3.3:1 and 2:1 respectively. A probable
reason for this pattern could be explained by an increased
susceptibility of perinatal disorders in the male new-born
population [20]. In contrast, in the non-AKI group the reverse
was found, with a male-to-female ratio of 1:1.12.
Urine NGAL has been studied in different population
groups as a novel biomarker for the early detection of AKI,
with over 400 published articles from animal models to hu-
man studies. However, few studies have been conducted using
urine NGAL as an early biomarker of kidney injury in neo-
nates. Several cut-off points ranging from 80 to 550 ng/ml
have been used to determine the best sensitivity and specific-
ity of urine NGAL [21, 22].
The sensitivity and specificity of NGAL in detecting renal
impairment, as indicated by serum creatinine greater than
133 μmol/l, were 88 and 56 % respectively, with an AUC of
0.724. The aforementioned findings are very similar to a meta-
analysis of urine NGAL, displaying pooled data for research-
based assays. It showed a sensitivity of 76.9%, a specificity of
83.4 %, AUC of 0.732 and an NGAL cut-off of 246.9 μmol/l
[23].
Various studies have also shown that in research-based
assays higher variability for cut-off and lower specificity
prevail, as is the case in this present study. To what extent
these cut-off values concur is currently unknown and requires
further investigation.
The few studies carried out in neonates show that urine
NGAL has moderate to excellent efficacy as a predictor of
AKI. This study showed an overall moderate efficacy (AUC
0.724) in predicting AKI. The differences in these studies
could be related to the number of patients enrolled, the prev-
alence of the disease and whether the study was designed
primarily for identifying NGAL levels to diagnose AKI.
The diagnostic performance of a biomarker does not only
depend on its ability to detect injury, but also on the disease
prevalence and its sensitivity and specificity. The sensitivity of
a new biomarker can be reduced from its true sensitivity,
especially if the gold standard is not 100 % sensitive or
specific. This is true for the present study as creatinine is not
100 % sensitive and specific, thereby affecting the true sensi-
tivity of urine NGAL in this study [24].
Since sensitivity and specificity do not give us the proba-
bility that the test will give the correct diagnosis, we calculated
the positive and negative predictive values. For the present
study, these were 30% (95 % CI 17.35–44.9) and 95 % (95 %
CI 84.5–99.3) respectively. Similar results were seen in a
clinical study by Xin et al. [25] on the role of urine NGAL
and IL-18 in predicting AKI after surgery. They found that
27.2 % of the patients enrolled in the study had AKI. At a cut-
off of 250 ng/ml of urine NGAL, the positive and negative
predictive values were 58.3 and 90.5 % respectively.
The positive and negative likelihood ratios for urine NGAL
at >250 ng/ml were 2.0 (95 % CI 1.45–2.73) and 0.2 (95 % CI
0.06–0.83) respectively. This means that a positive test result,
that is, urine NGAL >250 ng/ml, is twice as likely to be seen
in a child with AKI as opposed to one without AKI.
The negative likelihood ratio indicates that any value of urine
NGAL <250 ng/ml is associated with the absence of AKI. Our
negative likelihood ratio is far away from 1, indicating strong
evidence of the absence of AKI if urine NGAL is <250 ng/ml.
Biochemical derangements of urine NGAL on day 1 cor-
related well with severity of HIE and mortality. The current
study revealed significant median levels of urine NGAL for
severe HIE and death. Urine NGAL at 250 ng/ml on day 1,
correlated well with the severity of HIE and outcome (p=
0.002; odds ratio=8.9). Comparable findings in the literature
also support these study findings of urine NGAL as an indi-
cator of mortality [21, 26–28].
No statistically significant association was seen between
urine NGAL and the grade of asphyxia. However, when
comparing this with the severity of HIE, there was a signifi-
cant association. This difference can be attributed to the fact
that the Apgar scoring is subjective and is not a surrogate
marker of AKI, whereas HIE scoring is more objective.
An important finding in this study is how NGAL behaves
as AKI progresses. The general trend of NGAL shows similar
levels at days 1 and 3, with no statistically significant differ-
ence. However, a comparison of levels of urine NGAL on day
1 for patients with and without AKI shows statistically signif-
icantly higher levels of NGAL in the former than in the latter.
Likewise, a similar trend is seen on day 3. Sarafidis et al.
demonstrated that the serum creatinine levels 1 week after
birth were similar in those who had an acute rise and those
who did not [13]. This means either that the serum creatinine
is not sensitive enough to detect complete recovery of kidney
function or that the glomerular filtration rate improves faster
than tubular repair [7].
There were a number of limitations to the study. A preci-
sion error of 10 % was used for sample size estimation instead
of the conventional 5 %. This level of precision was adopted
because of limitations of resources and study time available.
Although serum creatinine is the gold standard, it is not the
ideal marker as creatinine provides an estimate of function,
not injury, and therefore is not 100 % accurate in detecting
AKI. This means that a patient may have AKI, but serum
creatinine does not rise until significant loss of function oc-
curs. This present study used serum creatinine as the gold
standard for the definition of AKI, which could have ham-
pered the true sensitivity and specificity of urine NGAL, as
some patients with evidence of high NGAL, but without any
elevation in serum creatinine, were categorised in the non-
AKI group. Serum creatinine mystifies early documentation
of AKI and lacks the sensitivity for the detection of tubular
injury.
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Conclusion
This study has shown a relatively high prevalence (56 %) of
AKI using urine NGAL, and has also shown that male new-
borns are affected more than their female counterparts. AKI
was more frequently present in babies with severe HIE than in
those without.
Urine NGAL is significantly elevated on day 1 in term
neonates with AKI compared with those without. Increased
urine NGAL concentration is an early marker of AKI. Urine
NGAL is also a good screening test owing to its high sensi-
tivity. Likewise, urine NGAL is a significant predictor of
mortality and severity of HIE, indicating that this biomarker
has both diagnostic and prognostic relevance.
Recommendations
For more accurate prevalence estimation, future definitions of
AKI will need improvement with a universal consensus state-
ment and incorporation of clinical end-points, such as mortal-
ity and renal replacement therapy.
Further large multicentre prospective randomised con-
trolled trials are required in the neonatal population for the
evaluation of urine NGAL as a biomarker for AKI.
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